1887

Abstract

Wild-type human p53 and a series of p53 point mutants isolated from Burkitt's lymphoma (BL) cell lines were tested for their ability to inhibit DNA synthesis in a p53-negative BL cell line and to bind and be degraded by the human papillomavirus type 16 E6 protein. All the mutants lost the wild-type ability to inhibit DNA synthesis, demonstrating that they are all functionally altered. Binding to E6 and consequent degradation of the p53 mutants frequently correlated with changed suppressor properties in BL cells.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-74-5-803
1993-05-01
2022-09-30
Loading full text...

Full text loading...

/deliver/fulltext/jgv/74/5/JV0740050803.html?itemId=/content/journal/jgv/10.1099/0022-1317-74-5-803&mimeType=html&fmt=ahah

References

  1. Baker S. J., Markowitz S., Fearon E. R., Willson J. K. V., Vogelstein B. 1990; Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912–915
    [Google Scholar]
  2. Banks L., Matlashewski G., Crawford L. 1986; Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. European Journal of Biochemistry 159:529–534
    [Google Scholar]
  3. Ciechanover A., Digiuseppe J. A., Bercovich B., Orian A., Richter J. D., Schwartz A. L., Brodeur G. M. 1991; Degradation of nuclear oncoproteins by the ubiquitin system in vitro. Proceedings of the National Academy of Sciences, U.S.A. 88:139–143
    [Google Scholar]
  4. Crook T., Vousden K. H. 1992; Properties of p53 mutations detected in primary and secondary cervical cancers suggests mechanisms of metastasis and involvement of environmental carcinogens. EMBO Journal 11:3935–3940
    [Google Scholar]
  5. Crook T., Fisher C., Vousden K. H. 1991a; Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression. Journal of Virology 65:505–510
    [Google Scholar]
  6. Crook T., Tidy J. A., Vousden K. H. 1991b; Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation. Cell 67:547–556
    [Google Scholar]
  7. Diller L., Kassel J., Nelson C. E., Gryka M. A., Litwak G., Gebhardt M., Bressac B., Ozturk M., Baker S. J., Vogelstein B., Friend S. H. 1990; p53 functions as a cell cycle control protein in osteosarcomas. Molecular and Cellular Biology 10:5772–5781
    [Google Scholar]
  8. Farrell P. J., Allan G. J., Shanahan F., Vousden K. H., Crook T. 1991; p53 is frequently mutated in Burkitt’s lymphoma cell lines. EMBO Journal 10:2879–2887
    [Google Scholar]
  9. Fields S., Jang S. K. 1990; Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046–1049
    [Google Scholar]
  10. Gaidano G., Ballerini P., Gong J. Z., Inchirami G., Neri A., Newcomb E. W., Magrath I. T., Knowles D. M., Dalla-Favera R. 1991; p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. Proceedings of the National Academv of Sciences, U.S.A. 88:5413–5417
    [Google Scholar]
  11. Gannon J. V., Greaves R., Iggo R., Lane D. P. 1990; Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO Journal 9:1595–1602
    [Google Scholar]
  12. Ginsberg D., Mechta F., Yaniv M., Oren M. 1991; Wild-type p53 can down-modulate the activity of various promoters. Proceedings of the National Academy of Sciences, U.S.A. 88:9979–9983
    [Google Scholar]
  13. Hinds P. W., Finlay C. A., Quartin R. S., Baker S. J., Fearon E. R., Vogelstein B., Levine A. J. 1992; Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the ‘hot spot’ mutant phenotypes. Cell Growth and Differentiation I:571–580
    [Google Scholar]
  14. Hirt B. 1967; Selective extraction of polyoma DNA from infected mouse cell cultures. Journal of Molecular Biology 26:365–369
    [Google Scholar]
  15. Hollstein M., Sidransky D., Vogelstein B., Harris C. C. 1991; p53 mutations in human cancers. Science 253:49–53
    [Google Scholar]
  16. Huibregtse J. M., Scheffner M., Howley P. M. 1991; A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO Journal 10:4129–4135
    [Google Scholar]
  17. Lane D. P. 1992; p53, guardian of the genome. Nature, London 358:15–16
    [Google Scholar]
  18. Lane D. P., Benchimol S. 1990p53 oncogene or anti-oncogene?. Genes and Development 4:1–8
    [Google Scholar]
  19. Lane D. P., Crawford L. V. 1979; T antigen is bound to a host protein in SV40-transformed cells. Nature, London 278:261–263
    [Google Scholar]
  20. Lau R., Packham G., Farrell P. J. 1992; Differential splicing of Epstein-Barr virus immediate early RNA. Journal of Virology 66:6233–6238
    [Google Scholar]
  21. Levine A. J. 1990; The p53 protein and its interactions with the oncogene products of the small DNA tumor viruses. Virology 177:419–426
    [Google Scholar]
  22. Medcalf E. A., Takahashi T., Chiba I., Minna J., Milner J. 1992; Temperature-sensitive mutants of p53 associated with human carcinoma of the lung. Oncogene 1:71–76
    [Google Scholar]
  23. Mercer W. E., Shields M. T., Amin M., Sauve G. J., Appella E., Romano J. W., Ullrich S. J. 1990; Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proceedings of the National Academy of Sciences, U.S.A. 87:6166–6170
    [Google Scholar]
  24. Raycroft L., Wu H., Lozano G. 1990; Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene. Science 249:1049–1051
    [Google Scholar]
  25. Rodrigues N. R., Rowan A., Smith M. E. F., Kerr I. B., Bodmer W. F., Gannon J. V., Lane D. P. 1990; p53 mutations in colorectal cancer. Proceedings of the National Academy of Sciences, U.S.A. 87:7555–7559
    [Google Scholar]
  26. Sarnow P., Williams J., Levine A. J. 1982; Adenovirus Elb-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54kd cellular protein in transformed cells. Cell 28:387–394
    [Google Scholar]
  27. Scheffner M., Werness B. A., Huibregtse J. M., Levine A. J., Howley P. M. 1990; The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129–1136
    [Google Scholar]
  28. Shaulsky G., Goldfinger N., Rotter V. 1991; Alterations in tumor development in vivo mediated by expression of wild type or mutant p53 proteins. Cancer Research 51:5232–5237
    [Google Scholar]
  29. Tarada K., Ono Y. 1989; Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. Journal of Virology 63:445–449
    [Google Scholar]
  30. Werness B. A., Levine A. J., Howley P. M. 1990; Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248:76–79
    [Google Scholar]
  31. Wiman K. G., Magnusson K. P., Ramqvist T., Klein G. 1991; Mutant p53 detected in a majority of Burkitt lymphoma cell lines by monoclonal antibody PAb240. Oncogene 6:1633–1639
    [Google Scholar]
  32. Yewdell J. W., Gannon J. V., Lane D. P. 1986; Monoclonal antibody analysis of p53 expression in normal and transformed cells. Journal of Virology 59:444–452
    [Google Scholar]
  33. Yonish-Rouach E., Resnitzky D., Lotem J., Sachs L., Kimchi A., Oren M. 1991; Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature, London 352:345–347
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-74-5-803
Loading
/content/journal/jgv/10.1099/0022-1317-74-5-803
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error